SCHEMBL6480684

SCHEMBL6480684

CCCS(=O)(=O)NCC(C)Oc1ccc(-c2ccc(NC(=O)C(C)C)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
MTNR1B P49286 2/20 0.39
GRIA4 P48058 1/20 0.38
RECQL P46063 1/20 0.38
ALDH1A1 P00352 4/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
MTNR1A P48039 1/20 0.37
POLB P06746 2/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
LMNA P02545 1/20 0.37
ALOX12 P18054 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6482779 0.90 SMN1; SMN2 (0.44) CA1CA2CA12CA9MTNR1B
SCHEMBL6482324 0.87 GRIA4 (0.46) CA2CA12MTNR1BGRIA4MAPT
SCHEMBL6480681 0.85 GRIA4 (0.48) CA1CA2CA12CA9MTNR1B
SCHEMBL6475448 0.84 ERCC1 (0.39) CA1CA2MTNR1BGRIA4RECQL
SCHEMBL6481831 0.83 GAA (0.40) CA1CA2CA12CA9ALDH1A1
SCHEMBL6475287 0.82 SMN1; SMN2 (0.47) CA1CA2CA12CA9MTNR1B
SCHEMBL6480651 0.82 GRIA4 (0.46) MTNR1BGRIA4MAPTMEN1KMT2A
SCHEMBL6474393 0.82 GRIA4 (0.43) CA2CA12CA9MTNR1BGRIA4
SCHEMBL6475297 0.82 GRIA4 (0.48) MTNR1BGRIA4ALDH1A1MAPTMTNR1A
SCHEMBL6482161 0.82 MTNR1A (0.49) MTNR1BGRIA4RECQLMTNR1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 CA1 1199/4885CA2 1773/4885CA12 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.